The most consistent signal concerns PDE5 inhibitors for erectile dysfunction in men with SCI, whereas most other interventions across MS, stroke/ABI, PD, and epilepsy are supported by low- or very low-certainty evidence that should be interpreted as hypothesis-generating. Here, PDE5A is linked to myeloid sarcoma.